Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY‐3+)
Keyword(s):
Keyword(s):
Keyword(s):
2015 ◽
Vol 51
(4)
◽
pp. 390-403
◽
Keyword(s):
2010 ◽
Vol 82
(10)
◽
pp. 1647-1654
◽
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
2017 ◽
Vol 15
(3)
◽
pp. 431-437.e2
◽
Keyword(s):
Keyword(s):
Keyword(s):